MX2021002215A - Derivados de tetrahidropiridopirimidina como moduladores de ahr. - Google Patents

Derivados de tetrahidropiridopirimidina como moduladores de ahr.

Info

Publication number
MX2021002215A
MX2021002215A MX2021002215A MX2021002215A MX2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A
Authority
MX
Mexico
Prior art keywords
tetrahydropyridopyrimidine
derivatives
compounds
ahr modulators
ahr
Prior art date
Application number
MX2021002215A
Other languages
English (en)
Inventor
Antonio Mete
Hitchin James R
Mark Graham
John King-Underwood
Philip Vellacott Thorne
Original Assignee
Jaguahr Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaguahr Therapeutics Pte Ltd filed Critical Jaguahr Therapeutics Pte Ltd
Publication of MX2021002215A publication Critical patent/MX2021002215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a compuestos de la Fórmula (I), que son adecuados como moduladores de AhR, en particular, inhibidores de AhR. La divulgación también se refiere a composiciones que comprenden dichos compuestos y al uso de dichos compuestos o composiciones en el tratamiento, en particular, en el tratamiento del cáncer. La divulgación se refiere además a métodos para preparar dichos compuestos.
MX2021002215A 2018-08-24 2019-08-23 Derivados de tetrahidropiridopirimidina como moduladores de ahr. MX2021002215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201807244X 2018-08-24
PCT/EP2019/072641 WO2020039093A1 (en) 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators

Publications (1)

Publication Number Publication Date
MX2021002215A true MX2021002215A (es) 2021-07-15

Family

ID=67982013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002215A MX2021002215A (es) 2018-08-24 2019-08-23 Derivados de tetrahidropiridopirimidina como moduladores de ahr.

Country Status (14)

Country Link
US (1) US20210332041A1 (es)
EP (1) EP3841102B1 (es)
JP (1) JP2021535213A (es)
KR (1) KR20210049135A (es)
CN (1) CN112739698A (es)
AU (1) AU2019323714A1 (es)
BR (1) BR112021003529A2 (es)
CA (1) CA3110402A1 (es)
IL (1) IL281023A (es)
MX (1) MX2021002215A (es)
PH (1) PH12021550382A1 (es)
SG (1) SG11202101441SA (es)
WO (1) WO2020039093A1 (es)
ZA (1) ZA202100931B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
WO2021173082A1 (en) 2020-02-26 2021-09-02 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
CN115443276A (zh) * 2020-04-17 2022-12-06 东亚St株式会社 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
TW200521119A (en) * 2003-08-05 2005-07-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
NZ591427A (en) 2008-10-02 2012-12-21 Respivert Ltd P38 map kinase inhibitors
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2011022213A1 (en) * 2009-08-17 2011-02-24 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine pde10 inhibitors
CN103179968B (zh) 2010-07-27 2017-10-03 波士顿大学管理委员会 作为癌症疗法的芳烃受体(AhR)调节剂
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof
CN109863140B (zh) 2016-05-25 2023-02-21 拜耳医药股份有限公司 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺

Also Published As

Publication number Publication date
CA3110402A1 (en) 2020-02-27
PH12021550382A1 (en) 2021-12-13
SG11202101441SA (en) 2021-03-30
KR20210049135A (ko) 2021-05-04
AU2019323714A1 (en) 2021-03-25
CN112739698A (zh) 2021-04-30
WO2020039093A1 (en) 2020-02-27
IL281023A (en) 2021-04-29
ZA202100931B (en) 2021-10-27
EP3841102A1 (en) 2021-06-30
BR112021003529A2 (pt) 2021-05-18
EP3841102B1 (en) 2022-09-14
US20210332041A1 (en) 2021-10-28
JP2021535213A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
CR20200518A (es) Piridozinonas como inhibidores de parp7
CR20190478A (es) Inhibidores de pd-1/pd-l1
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2022005780A (es) Moduladores de receptores estrogenicos.
MX2019007234A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
WO2019023315A3 (en) RAC INHIBITORS
MX2024002391A (es) Inhibidores de indolina de kif18a.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer